

## Polatuzumab

|                   |   |
|-------------------|---|
| Cat. No.:         | HY-P99042   |
| CAS No.:          | 2279068-37-8  |
| Molecular Weight: | 145260  |
| Target:           | ADC Antibody  |
| Pathway:          | Antibody-drug Conjugate/ADC Related   |
| Storage:          | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

#### Description

Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b<sup>[1]</sup>.

### REFERENCES

[1]. Estelle Bourbon, et al. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. Expert Opin Investig Drugs. 2020 Oct;29(10):1079-1088.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA